Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what steps the (a) Human Fertilisation and Embryology Authority and (b) Medicines and Healthcare Products Regulatory Agency are taking to collect information on the drugs and dosages used in treating women with fertility drugs.

The Human Fertilisation and Embryology Authority does not collect information on the fertility drugs and dosages used in the treatment of women.

The Medicines and Healthcare products Regulatory Agency (MHRA) continuously monitors the safety of all medicines on the United Kingdom market and takes regulatory action as necessary when safety issues are identified.

The Yellow Card Scheme is the UK system for collecting and monitoring information on suspected adverse drug reactions (ADRs) experienced post marketing. The scheme is run by the MHRA on behalf of the Commission on Human Medicines and it relies on the voluntary reporting of suspected ADRs by health professionals and patients. There is also a legal obligation for pharmaceutical companies to report serious side effects for their products. The scheme collects reports of suspected ADRs from across the whole UK and includes all medicines.